

The Innovative Medicines Initiative (IMI)



Call & Evaluation Process



- Participation & Funding
- Call & Evaluation Process

IMI Call Process is Different from FP7 Call Process



1. Research Topics are approved by the IMI Governing Board (EFPIA and European Commission) based on a proposal from EFPIA Research Directors Group.
2. The private consortium is established by the EFPIA Research Directors Group
3. The applicant consortium submits an Expression of Interest without involving the private consortium
4. The public-private consortium is established at the stage 1 of the peer review process.

Rules for Participation in IMI Consortium



- Independent legal entities
- Capacity to carry out work themselves
- Research performed in Europe or country associated with the 7th framework programme
- At least 2 EFPIA legal entities and 2 non-EFPIA legal entities per project

Eligibility for IMI funding



Eligible for funding	Non-eligible for funding
<ul style="list-style-type: none">– Academia– SMEs (EU definition)– Patient Organisations– Other non-for-profit legal entities	<ul style="list-style-type: none">– EFPIA companies– Other companies not falling within the EU definition of SMEs

Funding is according to EU State Aid rules



Project Costs Calculation:

100% of direct costs + overheads (= 20% of direct costs minus subcontracting)

Reimbursement


In-kind contribution

Applicant Eligible for Funding Re-Imbursement Calculation:


75% of costs of research activities
100% of costs of management activities

EFPIA Companies
Calculation of in-kind contribution:
Project Costs Calculation

Funding of Research Projects




Funding will be allocated to IMI projects until 2013 but research will be supported until 2017



- Participation & Funding
- Call & Evaluation Process

Call & Evaluation Process Overview



Call & Evaluation Process

Call definition



Research Agenda

Call Topics

Call

Call definition

Description of the Call Topics (1)



0. Topic Code

1. Title

2. Project description

3. Key deliverables of the project

4. EFPIA participants in the projects

5. Role of EFPIA participants in the projects

6. Indicative duration of the project

7. Indicative total in kind contribution from the EFPIA companies

8. Indicative expectations from the “Applicant consortium”

9. Indicative financial support from IMI JU to the "Applicant Consortium"

Description of the Call Topics (2)



- IMI research projects will often be multidisciplinary and addressing translation medicine challenges. Integrated approaches between nonclinical and clinical disciplines are often required.
- The successful applicants consortium is expected to include expertise for all aspects of the areas mentioned in the description of the call topics.

Call & Evaluation Process

Stage 1



Research Agenda

Call Topics

Call

Call definition

Expression of Interest

1st Peer Review

Invitation to Submit Full
Project Proposal

Stage 1: Scientific excellence

≈ 5 months



Description of the Expression of Interest



1. Composition of the applicants consortium
2. Abstract (1/2 pages)
3. Science (3 pages)
4. Knowledge Management (1/2 page)
5. Training and Education (1/2 page)
6. Outstanding issues (1/2 page)
7. Budget plan (1/2 page)

**Written by the Public Consortium:
i.e. academia, SMEs, regulators, patients organisations
(without pharmaceutical companies)**

Peer Review Stage 1



- **Peer Review Committees**

- One Standing Peer Review Committee per Pillar of the Strategic Research Agenda
- Assisted by ad hoc experts relevant to the call topics
- EFPIA Consortia members participate in evaluation of Expressions of Interest

- **Responsibility**

- To evaluate science of Expressions of Interest

- **Composition**

- Members reflecting a balance of public-private research expertise

- **Decision Making**

- By consensus between all experts

Call & Evaluation Process

Stage 2



Description of the Full Project Proposal



- Written jointly by the EFPIA Consortium and Applicant Consortium members
- Full description of research activities
 - Who, when, and how much
- Will need a draft Project Agreement before submission
 - IPR sharing agreed between all partners

**Written by the Public Private Consortium:
i.e. academia, SMEs, regulators, patients organisations
and pharmaceutical companies**

Peer Review Stage 2



- **Peer Review Committees**

- One Standing Peer Review Committee per Pillar of the Strategic Research Agenda
- Assisted by ad hoc experts relevant to the call topics
- No EFPIA Consortia members

- **Responsibility**

- To evaluate Full Proposals based on science and feasibility

- **Composition**

- Members reflecting a balance of public-private research expertise

- **Decision Making**

- By consensus between all experts

Call & Evaluation Process



Timelines



30 April 2008:	Publication of the IMI Call
1 June 2008:	Opening of period for submitting Expressions of Interest
15 July 2008:	Deadline for Expressions of Interest
November 2008:	Deadline for Full Project Proposals
December 2008:	Deadline for selection
February 2009:	Signature of Grant Agreement
March 2009:	Start of research project